Holen Sie sich die Stockscreener-App
47.91
5.00%
-2.52
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
FY2025 EPS Estimate for CRISPR Therapeutics Cut by Analyst - MarketBeat
Crispr therapeutics CEO sells $1.01 million in stock By Investing.com - Investing.com Nigeria
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 3.4%Here's Why - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 18,360 Shares - MarketBeat
Crispr therapeutics CEO sells $1.01 million in stock - Investing.com India
CRISPR Therapeutics AG CEO Samarth Kulkarni Sells Shares - TradingView
Stock Traders Purchase High Volume of CRISPR Therapeutics Call Options (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 2%What's Next? - MarketBeat
FY2025 EPS Forecast for CRISPR Therapeutics Cut by Analyst - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Lifted by Allworth Financial LP - MarketBeat
Crispr therapeutics COO Bruno Julianne sells $17,582 in stock By Investing.com - Investing.com South Africa
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap UpShould You Buy? - MarketBeat
CRISPR set to snap six days of gains as shares trade in red - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 4.1%Time to Sell? - MarketBeat
Market Whales and Their Recent Bets on CRSP Options - Benzinga
CRISPR Therapeutics: Navigating a Genetic Revolution Amid Healthcare Challenges - Reporteros del Sur -
CRISPR Therapeutics AG (CRSP): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - Nasdaq
Van ECK Associates Corp Boosts Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Therapeutics' general counsel sells shares worth $619,492 By Investing.com - Investing.com Australia
Crispr Therapeutics' general counsel sells shares worth $619,492 - Investing.com India
Crispr therapeutics CEO sells shares worth over $1 million - Investing.com
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
CRISPR Therapeutics (CRSP) Projected to Post Earnings on Wednesday - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 3.4%Here's Why - MarketBeat
Cantor Fitzgerald Reiterates "Neutral" Rating for CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
Brokerages Set CRISPR Therapeutics AG (NASDAQ:CRSP) Target Price at $74.50 - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Given New $82.00 Price Target at Citigroup - MarketBeat
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year - Investing.com Australia
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year By Investing.com - Investing.com South Africa
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell? - Nasdaq
This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Morgan Stanley Forecasts Strong Price Appreciation for CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Upgraded by Evercore ISI to Outperform Rating - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Outperform at Evercore ISI - MarketBeat
Research Analysts Offer Predictions for CRSP Q1 Earnings - MarketBeat
CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last? - MSN
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? - Benzinga
Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US - GlobeNewswire Inc.
CRISPR Therapeutics (NASDAQ:CRSP) Given New $120.00 Price Target at Truist Financial - MarketBeat
Q1 Earnings Forecast for CRSP Issued By Leerink Partnrs - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Sell at StockNews.com - MarketBeat
Stifel Nicolaus Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $49.00 - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
CRISPR Therapeutics (CRSP): Tailored Genetic Engineering - Securities.io
How to Take Advantage of moves in (CRSP) - Stock Traders Daily
Evercore ISI Group Upgrades CRISPR Therapeutics (LSE:0VRQ) - Nasdaq
Capital Advisors Inc. OK Buys 9,681 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
BRIEF-Crispr Therapeutics AG shares open at $15 in debut, above IPO price of $14/shr - Wealth Management
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $32.00 at Morgan Stanley - MarketBeat
Stifel cuts CRISPR Therapeutics target to $49, holds rating - MSN
Why CRISPR Therapeutics (CRSP) Soared on Friday? - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap Up Following Strong Earnings - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Given New $56.00 Price Target at Barclays - MarketBeat
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):